Hostname: page-component-6766d58669-zlvph Total loading time: 0 Render date: 2026-05-24T07:54:24.809Z Has data issue: false hasContentIssue false

Strategic investment in tuberculosis control in the Republic of Bulgaria

Published online by Cambridge University Press:  18 November 2019

T. N. Doan*
Affiliation:
Department of Medicine at The Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, Queensland, Australia
T. Varleva
Affiliation:
Promotion and Prevention of Diseases and Addictions, Ministry of Health, Sofia, Bulgaria
M. Zamfirova
Affiliation:
Promotion and Prevention of Diseases and Addictions, Ministry of Health, Sofia, Bulgaria
M. Tyufekchieva
Affiliation:
Promotion and Prevention of Diseases and Addictions, Ministry of Health, Sofia, Bulgaria
A. Keshelava
Affiliation:
Promotion and Prevention of Diseases and Addictions, Ministry of Health, Sofia, Bulgaria Programmes Management Unit, Ministry of Health, Sofia, Bulgaria
K. Hristov
Affiliation:
Promotion and Prevention of Diseases and Addictions, Ministry of Health, Sofia, Bulgaria Programmes Management Unit, Ministry of Health, Sofia, Bulgaria
A. Yaneva
Affiliation:
Promotion and Prevention of Diseases and Addictions, Ministry of Health, Sofia, Bulgaria Programmes Management Unit, Ministry of Health, Sofia, Bulgaria
B. Gadzheva
Affiliation:
Promotion and Prevention of Diseases and Addictions, Ministry of Health, Sofia, Bulgaria Programmes Management Unit, Ministry of Health, Sofia, Bulgaria
S. Zhang
Affiliation:
The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland
S. Irbe
Affiliation:
The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland
R. Ragonnet
Affiliation:
Department of Medicine at The Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia The Burnet Institute, Melbourne, Victoria, Australia School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
E. S. McBryde
Affiliation:
Department of Medicine at The Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, Queensland, Australia
J. M. Trauer
Affiliation:
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
*
Author for correspondence: T. N. Doan, E-mail: tan.doan@uqconnect.edu.au
Rights & Permissions [Opens in a new window]

Abstract

As Bulgaria transitions away from Global Fund grant, robust estimates of the comparative impact of the various response strategies under consideration are needed to ensure sustained effectiveness of the tuberculosis (TB) programme. We tailored an established mathematical model for TB control to the epidemic in Bulgaria to project the likely outcomes of seven intervention scenarios. Under existing programmatic conditions projected forward, the country's targets for achieving TB elimination in the coming decades will not be achieved. No interventions under consideration were predicted to accelerate the baseline projected reduction in epidemiological indicators significantly. Discontinuation of the ‘Open Doors’ program and activities of non-governmental organisations would result in a marked exacerbation of the epidemic (increasing incidence in 2035 by 6–8% relative to baseline conditions projected forward). Changing to a short course regimen for multidrug-resistant TB (MDR-TB) would substantially decrease MDR-TB mortality (by 21.6% in 2035 relative to baseline conditions projected forward). Changing to ambulatory care for eligible patients would not affect TB burden but would be markedly cost-saving. In conclusion, Bulgaria faces important challenges in transitioning to a primarily domestically-financed TB programme. The country should consider maintaining currently effective programs and shifting towards ambulatory care to ensure program sustainability.

Information

Type
Original Paper
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © The Author(s) 2019
Figure 0

Table 1. Simulated interventions

Figure 1

Fig. 1. Epidemiological calibration results. The blue shaded areas represent model estimates. The black lines and hatched areas are mean values and confidence limits, respectively, for indicator data from the WHO Global TB report (2016 and 2017). Data from the WHO Global TB Report 2017 were used for the years from 2000 to 2016. As the WHO Global TB Report 2017 did not report data prior to 2000, the WHO Global TB Report 2016 was used for data points for the years that were not included in the 2017 report (1990 to 1999). The red lines in the Incidence panel indicate the WHO incidence data points against which the model was calibrated. Grey lines represent the SDG targets for 2030, the End TB Strategy targets for 2035 and the interim milestones for 2020 and 2025. Units of all horizontal axes are calendar years and units of vertical axes are: incidence, per 100 000 per year; mortality, per 100 000 per year; prevalence per 100 000; notifications, absolute number.

Figure 2

Fig. 2. Predicted effect of interventions on overall epidemic. Black, baseline; thin grey, the SDG targets for 2030, the End TB Strategy targets for 2035 and the interim milestones for 2020 and 2025; light blue, short course regimen for MDR-TB (Scenario 1); yellow, scale-up DST coverage in culture-positive TB cases (Scenario 2); green, scale-up food vouchers for all patients under treatment (Scenario 3); purple, discontinue Open Doors program (Scenario 5); orange, discontinue NGO activities (Scenario 6); thick grey, combination of scenarios 1, 2, 3 and 4 (Scenario 7); dashed black, all transmission completely ceases from 2017 onwards. Note that transitioning from inpatient care to ambulatory care for smear-negative and extrapulmonary DS-TB patients (Scenario 4) is not shown in the Figure as it overlaps with the baseline, given the assumption that the two models of care have comparable health outcomes. Scenario 2 also closely overlaps baseline (in its impact on all forms of TB) and so is not visible. Units of all horizontal axes are calendar years and units of vertical axes are: incidence, per 100 000 per year; mortality, per 100 000 per year; prevalence per 100 000; notifications, absolute number.

Figure 3

Fig. 3. Predicted effect of interventions on disease burden in population risk groups. Black, baseline; light blue, short course regimen for MDR-TB (Scenario 1); yellow, scale-up DST coverage in culture-positive TB cases (Scenario 2); green, scale-up food vouchers for all patients under treatment (Scenario 3); purple, discontinue Open Doors program (Scenario 5); orange, discontinue NGO activities (Scenario 6); thick grey, combination of scenarios 1, 2, 3 and 4 (Scenario 7); dashed black, all transmission completely ceases from 2017 onwards. Note that transitioning from inpatient care to ambulatory care for smear-negative and extrapulmonary DS-TB patients (Scenario 4) is not shown in the Figure as it overlaps with the baseline, given the assumption that the two models of care have comparable health outcomes. No risk refers to the remainder of the population not belonging to one of the three simulated risk groups. Units of all horizontal axes are calendar years and units of all vertical axes are events per 100 000 per year.

Figure 4

Fig. 4. Predicted effect of interventions on the burden of MDR-TB. Black, baseline; light blue, short course regimen for MDR-TB (Scenario 1); yellow, scale-up DST coverage in culture-positive TB cases (Scenario 2); green, scale-up food vouchers for all patients under treatment (Scenario 3); purple, discontinue Open Doors program (Scenario 5); orange, discontinue NGO activities (Scenario 6); thick grey, combination of scenarios 1, 2, 3 and 4 (Scenario 7); dashed black, all transmission completely ceases from 2017 onwards. Units of all horizontal axes are calendar years and units of vertical axes are: MDR-TB incidence, per 100 000 per year; MDR-TB mortality, per 100 000 per year; MDR-TB prevalence per 100 000; notifications, absolute number; MDR-TB percentage incidence, percentage.

Figure 5

Table 2. Predicted epidemiological and financial outcomes of interventions

Figure 6

Fig. 5. Comparison of baseline cost vs. scenario cost for each intervention. All costs are yearly cost in euros. Scenario 1, short course regimen for MDR-TB; scenario 2, scale-up DST coverage in culture-positive TB cases; scenario 3, scale-up food vouchers for all patients under treatment; scenario 4, transitioning from inpatient care to ambulatory care for smear-negative and extrapulmonary DS-TB patients; scenario 7, combination of scenarios 1, 2, 3 and 4. Negative and positive cost values indicate reduction and increase, respectively, of scenario costs relative to baseline. Negative and positive percentages indicate reduction and increase, relatively, of overall TB incidence (top panel) or overall TB mortality (bottom panel) relative to baseline.

Supplementary material: File

Doan et al. supplementary material

Doan et al. supplementary material

Download Doan et al. supplementary material(File)
File 5 MB